Central Statistical Monitoring
Analysis Results
Intelligent Grouping of analysis results based on machine learning.
Data Analysis
Analyse all Clinical and Operational data.
Compare Performance
See individual performance against overall site performance.
Hover over the toggles to discover the features.
FIND ATYPICAL SITES FAST
Central Statistical Monitoring can uncover unknown problems in the execution of your clinical trial. Use CSM to identify which Patients, Sites and/or Countries/Regions have atypical data patterns that lead to the discovery of operational issues.
Analysis Results
Intelligent Grouping of analysis results based on machine learning.
Data Analysis
Analyse all Clinical and Operational data.
Compare Performance
See individual performance against overall site performance.
Hover over the toggles to discover the features.
- Test all data you collect, both clinical and operational for issues
- Review the trending of results to identify improving or worsening scenarios
- Drill-down to the underlying data to ask further questions
- Manage all findings to conclusion in a unified issue management environment
- Uncover issues missed by other data quality control techniques
- Target your analysis to the data that matters
- Leverage machine learning to expedite the results to the study team
- Detect fraudulent patients or patient-related data
- Detect sloppiness in data recording, such as data propagation, rounding or digit preference
- Detect systemic errors in data recording, such as issues with medical equipment
- Detect rater bias or training issues
- Detect data timeliness issues such as implausible data accrual rates
Got a Question?
Whether you’re looking to get started or need support, we’re here to help!
Featured Resource
Tufts CSDD Impact Report
This study takes a proactive approach to understanding the dynamics between the enthusiasm around and adoption of RBQM, designed to enhance clinical trial quality and efficiency.
Featured Webinar
RBQM Adoption & ICH E6(R3) Updates
This recorded webinar dissects the Tufts CSDD Impact Report as well as new clinical trial execution models and ICH E6(R3) regulatory guidance updates.